Vijay Babu Pathi, , , Sunny Kumar, , , Asikul Sk, , , Subhankar Shee, , , Mrinal K. Ghosh*, , and , Biswadip Banerji*,
{"title":"异喹啉-萘醌杂种作为PARP-1抑制剂通过DNA损伤和ROS生成诱导胶质瘤细胞凋亡","authors":"Vijay Babu Pathi, , , Sunny Kumar, , , Asikul Sk, , , Subhankar Shee, , , Mrinal K. Ghosh*, , and , Biswadip Banerji*, ","doi":"10.1021/acs.jmedchem.5c01229","DOIUrl":null,"url":null,"abstract":"<p >We report a series of fused isoquinolinone–naphthoquinone hybrid molecules as PARP-1 inhibitors. Our efforts led to the identification of compounds <b>5c</b> and <b>5d</b>, which display potent PARP-1 inhibition in enzymatic assays with IC<sub>50</sub> values of 2.4 and 4.8 nM and demonstrated consistent antiproliferative activity in C6 glioma cells, with IC<sub>5</sub><sub>0</sub> values of 1.34 ± 0.02 and 1.35 ± 0.009 μM, respectively. Notably, both molecules showed similar efficacy in U87MG glioma cells with IC<sub>5</sub><sub>0</sub> values of 1.28 ± 0.03 and 1.33 ± 0.01 μM, respectively. <b>5c</b> and <b>5d</b> induced apoptosis in both glioma cells by promoting PARP cleavage, triggering DNA damage, and increasing ROS. Furthermore, they effectively inhibited cell migration and significantly reduced colony formation in both glioma cells. Thus, the results identify the hybrid isoquinolinone–naphthoquinone scaffolds (<b>5c</b> and <b>5d</b>) as a promising lead hit for PARP-1 inhibition in glioma, offering a new scaffold for future drug development.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 18","pages":"19153–19168"},"PeriodicalIF":6.8000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Isoquinolinone–Naphthoquinone Hybrids as Potent PARP-1 Inhibitors Induce Apoptosis in Glioma via DNA Damage and ROS Generation\",\"authors\":\"Vijay Babu Pathi, , , Sunny Kumar, , , Asikul Sk, , , Subhankar Shee, , , Mrinal K. Ghosh*, , and , Biswadip Banerji*, \",\"doi\":\"10.1021/acs.jmedchem.5c01229\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >We report a series of fused isoquinolinone–naphthoquinone hybrid molecules as PARP-1 inhibitors. Our efforts led to the identification of compounds <b>5c</b> and <b>5d</b>, which display potent PARP-1 inhibition in enzymatic assays with IC<sub>50</sub> values of 2.4 and 4.8 nM and demonstrated consistent antiproliferative activity in C6 glioma cells, with IC<sub>5</sub><sub>0</sub> values of 1.34 ± 0.02 and 1.35 ± 0.009 μM, respectively. Notably, both molecules showed similar efficacy in U87MG glioma cells with IC<sub>5</sub><sub>0</sub> values of 1.28 ± 0.03 and 1.33 ± 0.01 μM, respectively. <b>5c</b> and <b>5d</b> induced apoptosis in both glioma cells by promoting PARP cleavage, triggering DNA damage, and increasing ROS. Furthermore, they effectively inhibited cell migration and significantly reduced colony formation in both glioma cells. Thus, the results identify the hybrid isoquinolinone–naphthoquinone scaffolds (<b>5c</b> and <b>5d</b>) as a promising lead hit for PARP-1 inhibition in glioma, offering a new scaffold for future drug development.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 18\",\"pages\":\"19153–19168\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01229\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01229","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Isoquinolinone–Naphthoquinone Hybrids as Potent PARP-1 Inhibitors Induce Apoptosis in Glioma via DNA Damage and ROS Generation
We report a series of fused isoquinolinone–naphthoquinone hybrid molecules as PARP-1 inhibitors. Our efforts led to the identification of compounds 5c and 5d, which display potent PARP-1 inhibition in enzymatic assays with IC50 values of 2.4 and 4.8 nM and demonstrated consistent antiproliferative activity in C6 glioma cells, with IC50 values of 1.34 ± 0.02 and 1.35 ± 0.009 μM, respectively. Notably, both molecules showed similar efficacy in U87MG glioma cells with IC50 values of 1.28 ± 0.03 and 1.33 ± 0.01 μM, respectively. 5c and 5d induced apoptosis in both glioma cells by promoting PARP cleavage, triggering DNA damage, and increasing ROS. Furthermore, they effectively inhibited cell migration and significantly reduced colony formation in both glioma cells. Thus, the results identify the hybrid isoquinolinone–naphthoquinone scaffolds (5c and 5d) as a promising lead hit for PARP-1 inhibition in glioma, offering a new scaffold for future drug development.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.